CN103118709A - 流感病毒基质2蛋白的胞外域、其表达系统和应用 - Google Patents

流感病毒基质2蛋白的胞外域、其表达系统和应用 Download PDF

Info

Publication number
CN103118709A
CN103118709A CN2011800257513A CN201180025751A CN103118709A CN 103118709 A CN103118709 A CN 103118709A CN 2011800257513 A CN2011800257513 A CN 2011800257513A CN 201180025751 A CN201180025751 A CN 201180025751A CN 103118709 A CN103118709 A CN 103118709A
Authority
CN
China
Prior art keywords
seq
polypeptide
polynucleotide
carrier
influenza virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800257513A
Other languages
English (en)
Chinese (zh)
Inventor
T·吉南
M·莱西
M·斯基多普鲁斯
N·迈托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Gaithersburg Inc
Original Assignee
Emergent Product Development Gaithersburg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Development Gaithersburg Inc filed Critical Emergent Product Development Gaithersburg Inc
Publication of CN103118709A publication Critical patent/CN103118709A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800257513A 2010-03-26 2011-03-28 流感病毒基质2蛋白的胞外域、其表达系统和应用 Pending CN103118709A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31823210P 2010-03-26 2010-03-26
US61/318,232 2010-03-26
PCT/US2011/030205 WO2011120045A1 (en) 2010-03-26 2011-03-28 Ectodomains of influenza matrix 2 protein, expression system, and uses thereof

Publications (1)

Publication Number Publication Date
CN103118709A true CN103118709A (zh) 2013-05-22

Family

ID=44673677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800257513A Pending CN103118709A (zh) 2010-03-26 2011-03-28 流感病毒基质2蛋白的胞外域、其表达系统和应用

Country Status (8)

Country Link
US (1) US20130115234A1 (cg-RX-API-DMAC10.html)
EP (1) EP2552490A4 (cg-RX-API-DMAC10.html)
JP (1) JP2013523096A (cg-RX-API-DMAC10.html)
CN (1) CN103118709A (cg-RX-API-DMAC10.html)
AU (1) AU2011230491A1 (cg-RX-API-DMAC10.html)
CA (1) CA2793772A1 (cg-RX-API-DMAC10.html)
SG (1) SG184155A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011120045A1 (cg-RX-API-DMAC10.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105002149A (zh) * 2014-04-22 2015-10-28 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
CN105018441A (zh) * 2014-04-22 2015-11-04 中国科学院生物物理研究所 流感病毒rna聚合酶结晶的方法
CN108373507A (zh) * 2018-01-18 2018-08-07 复旦大学 一种重组亚单位禽流感疫苗Sef4M2e
CN110290805A (zh) * 2017-01-03 2019-09-27 埃默杰克斯疫苗控股有限公司 通用流感疫苗组合物
CN118530314A (zh) * 2024-06-06 2024-08-23 中国科学院武汉病毒研究所 广谱型流感疫苗抗原片段、重组益生菌及应用
CN119350508A (zh) * 2024-10-22 2025-01-24 成都纳微金生物技术有限公司 带广谱表位的三价流感纳米颗粒疫苗及其应用
CN121337972A (zh) * 2025-12-16 2026-01-16 呼研所生物安全科技(广州)股份有限公司 流感病毒活疫苗及制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US10286062B2 (en) 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
WO2016131945A1 (en) * 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US20180162913A1 (en) * 2015-05-01 2018-06-14 Immunovaccine Technologies Inc. Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
EP4626470A2 (en) * 2022-11-29 2025-10-08 The Scripps Research Institute Vaccines containing novel nanoparticle scaffolds
WO2024196719A2 (en) * 2023-03-17 2024-09-26 Versatope Therapeutics, Inc. Membrane vesicles comprising multiple influenza antigens for vaccines

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913920A (zh) * 2003-12-10 2007-02-14 阿波维亚公司 流感免疫原和疫苗
CN101072795A (zh) * 2004-12-06 2007-11-14 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体及其制备和使用方法
CN101208105A (zh) * 2005-03-29 2008-06-25 威斯特研究所 复合抗原制剂及其使用方法
CN101309699A (zh) * 2005-08-31 2008-11-19 塞尔德克斯医疗有限公司 稳定化的病毒样颗粒和表位展示系统
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
CN101531719A (zh) * 2008-06-06 2009-09-16 江苏省农业科学院 一种禽流感基因工程多肽抗原
CN101643721A (zh) * 2009-08-17 2010-02-10 诺华生物科技（武汉）有限责任公司 广谱安全型动物用抗甲型流感病毒疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
UA82479C2 (uk) * 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
CN1280310C (zh) * 2004-09-29 2006-10-18 清华大学 具有防治流感作用的融合蛋白及其编码基因与应用
NZ556004A (en) * 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
US20090196915A1 (en) * 2007-08-21 2009-08-06 Gary Van Nest Composition and methods of making and using influenza proteins
CA2697373C (en) * 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913920A (zh) * 2003-12-10 2007-02-14 阿波维亚公司 流感免疫原和疫苗
CN101072795A (zh) * 2004-12-06 2007-11-14 麒麟麦酒株式会社 针对流感病毒m2蛋白的人单克隆抗体及其制备和使用方法
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
CN101208105A (zh) * 2005-03-29 2008-06-25 威斯特研究所 复合抗原制剂及其使用方法
CN101309699A (zh) * 2005-08-31 2008-11-19 塞尔德克斯医疗有限公司 稳定化的病毒样颗粒和表位展示系统
CN101531719A (zh) * 2008-06-06 2009-09-16 江苏省农业科学院 一种禽流感基因工程多肽抗原
CN101643721A (zh) * 2009-08-17 2010-02-10 诺华生物科技（武汉）有限责任公司 广谱安全型动物用抗甲型流感病毒疫苗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KI SEOK PARK等: "Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge", 《VIROLOGY》 *
SMITH,G.等: "matrix protein 2, partial（Influenza A virus (A/Indonesia/6/2005(H5N1))", 《GENBANK: ABW06379.1》 *
XU,K.M.等: "matrix protein 2, partial (Influenza A virus (A/partridge/Shantou/2158/2000(H9N2))", 《GENBANK: ABV48118.1》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105002149A (zh) * 2014-04-22 2015-10-28 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
CN105018441A (zh) * 2014-04-22 2015-11-04 中国科学院生物物理研究所 流感病毒rna聚合酶结晶的方法
CN105002149B (zh) * 2014-04-22 2018-04-06 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
CN110290805A (zh) * 2017-01-03 2019-09-27 埃默杰克斯疫苗控股有限公司 通用流感疫苗组合物
CN108373507A (zh) * 2018-01-18 2018-08-07 复旦大学 一种重组亚单位禽流感疫苗Sef4M2e
CN118530314A (zh) * 2024-06-06 2024-08-23 中国科学院武汉病毒研究所 广谱型流感疫苗抗原片段、重组益生菌及应用
CN118530314B (zh) * 2024-06-06 2025-09-30 中国科学院武汉病毒研究所 广谱型流感疫苗抗原片段、重组益生菌及应用
CN119350508A (zh) * 2024-10-22 2025-01-24 成都纳微金生物技术有限公司 带广谱表位的三价流感纳米颗粒疫苗及其应用
CN121337972A (zh) * 2025-12-16 2026-01-16 呼研所生物安全科技(广州)股份有限公司 流感病毒活疫苗及制备方法和应用

Also Published As

Publication number Publication date
JP2013523096A (ja) 2013-06-17
WO2011120045A1 (en) 2011-09-29
SG184155A1 (en) 2012-10-30
AU2011230491A1 (en) 2012-10-18
EP2552490A4 (en) 2013-12-18
CA2793772A1 (en) 2011-09-29
EP2552490A1 (en) 2013-02-06
US20130115234A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
US11497807B2 (en) Zoonotic disease RNA vaccines
US20230381301A1 (en) Respiratory virus nucleic acid vaccines
US20130115234A1 (en) Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
AU2016342048B2 (en) Broad spectrum influenza virus vaccine
CN102257135B (zh) 流感疫苗的生产
CN101636177A (zh) 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗
US20120141525A1 (en) Universal influenza vaccine based on recombinant modified vaccine ankara virus (mva)
JP2008522621A (ja) 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン
EP2976357B1 (en) Influenza nucleoprotein vaccines
JP2013523096A5 (cg-RX-API-DMAC10.html)
JP7849046B2 (ja) インフルエンザウイルスバックボーン
CN111481663B (zh) 一种流感病毒活疫苗及其制备方法
US20220275346A1 (en) Hantavirus antigenic composition
WO2010005474A1 (en) Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens
WO2023062515A1 (en) Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses there of
HK1183791A (en) Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
JP2005170945A (ja) インフルエンザ血球凝集素多価ワクチンの製造方法
JP3918949B2 (ja) インフルエンザ血球凝集素多価ワクチンの製造方法
JP2007314538A (ja) インフルエンザ血球凝集素多価ワクチンの製造方法
KR20130001559A (ko) 넓은 범위의 교차 방어능력을 갖는 신규한 보강 인플루엔자 백신
HK1163177A (en) Production of influenza vaccines
HK1163177B (en) Production of influenza vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183791

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130522

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183791

Country of ref document: HK